Maxim Group announced Brainstorm Cell Therapeutics BCLI (NYSE:BCLI), bumping up its stock price target to $8.00 today
- Updated: April 20, 2017
Just yesterday Brainstorm Cell Therapeutics BCLI (NYSE:BCLI) traded 1.23% higher at $4.07. Brainstorm Cell Therapeutics BCLI’s 50-day moving average is $4.06 and its 200-day moving average is $2.99. The last closing price is up 37.57% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.03% over the same time period. 198,975 shares of BCLI traded hands, down from an average trading volume of 261,681
In a report released on 04/20/2017 Maxim Group increased the stock price target of Brainstorm Cell Therapeutics BCLI (NYSE:BCLI) to $8.00 reporting a possible upside of 0.97%.
Previously on 3/31/2017, Maxim Group reported on Brainstorm Cell Therapeutics BCLI (NYSE:BCLI) increased the target price from $6.00 to $8.00. At the time, this indicated a possible upside of 0.84%.
Recent Performance Chart
Brainstorm Cell Therapeutics BCLI has 52 week low of $2.06 and a 52 week high of $5.10 and has a market capitalization of $0.
Brief Synopsis On Brainstorm Cell Therapeutics BCLI (NYSE:BCLI)
Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson's disease (PD), among others. Its subsidiary, Brainstorm Cell Therapeutics Ltd. (the Israeli Subsidiary), holds rights to commercialize the technology, NurOwn. NurOwn is in clinical development for the treatment of ALS. The Company has completed over two clinical trials of NurOwn in patients with ALS at Hadassah Medical Center (Hadassah). The first study, a Phase I/II safety and efficacy study of NurOwn in ALS patients administered either intramuscularly or intrathecally. The Company conducted Phase IIa combined (intramuscular and intrathecal) treatment, dose-escalating trial. It had completed treatment of over 10 patients in its ALS Phase IIa NurOwn dose-escalating clinical trial.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.